Skip to main content

Advertisement

Log in

Management of Hyperglycemia in Hospitalized Patients with Renal Insufficiency or Steroid-Induced Diabetes

  • Hospital Management of Diabetes (G Umpierrez, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Pharmacologic doses of glucocorticoids and chronic renal failure are challenging comorbidities and complications for safe and effective dosing of insulin for the management of hospitalized patients with diabetes. Glucocorticoids are used widely in hospitalized patients and will commonly provoke new-onset hyperglycemia in patients without a prior history of diabetes or will provoke severely uncontrolled hyperglycemia in patients with known diabetes. Insulin therapy is invariably necessary for the treatment of glucocorticoid-induced hyperglycemia and must be tailored to the pharmacodynamics of the glucocorticoid being given. Renal failure causes a decrease in the clearance of insulin, especially exogenous injected insulin. Dosing algorithms for hospitalized patients should be adjusted for patients with renal failure in order to minimize hypoglycemia. Many patients with type 2 diabetes will need little or no therapy after the development of end-stage renal failure. Care must be taken to avoid the overtreatment of hyperglycemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154:97–101.

    Article  PubMed  CAS  Google Scholar 

  2. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728–9.

    Article  PubMed  CAS  Google Scholar 

  3. •• Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15:469–74. The latest comprehensive review of this topic.

    Article  PubMed  Google Scholar 

  4. Braithwaite SS, Barr WG, Rahman A, Quddusi S. Managing diabetes during glucocorticoid therapy. How to avoid metabolic emergencies. Postgrad Med. 1998;104:163–6.

    Article  PubMed  CAS  Google Scholar 

  5. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12:358–62.

    PubMed  Google Scholar 

  6. Wood-Baker RR, Gibson PG, Hannay M, Walters EH, Walters JA. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005, (1):CD001288.

  7. Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284–9.

    Article  PubMed  CAS  Google Scholar 

  8. Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley PM. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax. 2009;64:857–62.

    Article  PubMed  CAS  Google Scholar 

  9. • Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab. 2011;96:1789–96. Once daily AM prednisolone’s effect to elevate blood glucose only lasts for 14–18 hours. An observation with important implications for insulin therapy in these patients.

    Article  PubMed  CAS  Google Scholar 

  10. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001;41:1180–94.

    Article  PubMed  CAS  Google Scholar 

  11. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179–85.

    Article  PubMed  CAS  Google Scholar 

  12. •• Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2012 May 31. [Epub ahead of print] An important cautionary study that shows that although hyperglycemia may be associated with a negative outcome, correction of the hyperglycemia with intensive insulin therapy may not always improve the outcome.

  13. • Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: Risk assessment and management. Diabetes Care. 2012;35:181–8. The latest comprehensive review of this complex evolving field.

    Article  PubMed  CAS  Google Scholar 

  14. Vincenti F, Friman S, Scheuermann E, et al. DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus): Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–14.

    Article  PubMed  CAS  Google Scholar 

  15. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69:588–95.

    Article  PubMed  CAS  Google Scholar 

  16. Thomas MC, Mathew TH, Russ GR, Rao MM, Moran J. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72:1321–4.

    Article  PubMed  CAS  Google Scholar 

  17. Ganji MR, Charkhchian M, Hakemi M, Nederi GH, Solymanian T, Saddadi F, Amini M, Najafi I. Association of hyperglycemia on allograft function in the early period after renal transplantation. Transplant Proc. 2007;39:852–4.

    Article  PubMed  CAS  Google Scholar 

  18. Wallia A, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ, Levitsky J. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89:222–6.

    Article  PubMed  Google Scholar 

  19. •• Wallia A, Parikh ND, O'Shea-Mahler E, Schmidt K, DeSantis AJ, Tian L, Levitsky J, Molitch ME. Glycemic control by a glucose management service and infection rates after liver transplantation. Endocr Pract. 2011;17:546–51. An important study validating the benefits of excellent inpatient glucose control in the liver transplant population.

    Article  PubMed  Google Scholar 

  20. Dhital SM, Shenker Y, Meredith M, David DB. A Retrospective Study Comparing Neutral Protamine Hagedorn Insulin with Glargine as Basal Therapy in Prednisone-Associated Diabetes Mellitus in Hospitalized Patients. Endocr Pract. 2012 July 11, [Epub ahead of print].

  21. • DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–76. The follow-up study to the DCCT that shows continuing renal benefits of intensive control for patients with type 1 diabetes.

    Article  PubMed  Google Scholar 

  22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.

    Article  PubMed  CAS  Google Scholar 

  23. Williams ME, Lacson Jr E, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006;70:1503–9.

    Article  PubMed  CAS  Google Scholar 

  24. Williams ME, Lacson Jr E, Wang W, Lazarus JM, Hakim R. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol. 2010;5:1595–601.

    Article  PubMed  Google Scholar 

  25. Kalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30:1049–55.

    Article  PubMed  Google Scholar 

  26. •• Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, Kalantar-Zadeh K. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012;61:708–15. Why we should aim for HBA1C 7 %–8% in our patients with diabetes and ESRD.

    Article  PubMed  CAS  Google Scholar 

  27. • Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011;171:1920–7. A large study of patients with diabetes and stage 3 and 4 chronic renal failure that shows that HBA1C less than 6.5 % or greater than 8 % are detrimental to patient outcome.

    Article  PubMed  Google Scholar 

  28. •• Kalantar-Zadeh K. A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Diabetes Care. 2012;35:1625–8. Why we should continue to use and trust HBA1C in patients with diabetes and ESRD.

    Article  PubMed  Google Scholar 

  29. Freedman BI. A Critical Evaluation of Glycated Protein Parameters in Advanced Nephropathy: A Matter of Life or Death: Time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care. 2012;35:1621–4.

    Article  PubMed  Google Scholar 

  30. • Moen MF, Zhan M, Hsu VD, Walker LD, Einhorn LM, Seliger SL, Fink JC. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1121–7. A comprehensive look at the risks and frequency of hypoglycemia in outpatients and inpatients with diabetes and renal failure.

    Article  PubMed  CAS  Google Scholar 

  31. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32:1153–7.

    Article  PubMed  Google Scholar 

  32. Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf. 2010;9:675–81.

    Article  PubMed  CAS  Google Scholar 

  33. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10:811–23.

    Article  PubMed  CAS  Google Scholar 

  34. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13:4–8.

    Article  PubMed  CAS  Google Scholar 

  35. Cano N. Bench-to-bedside review: glucose production from the kidney. Crit Care. 2002;6:317–21.

    Article  PubMed  Google Scholar 

  36. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391–8.

    Article  PubMed  CAS  Google Scholar 

  37. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin-treated Type 2 diabetic patients. Diabet Med. 2003;20:642–5.

    Article  PubMed  CAS  Google Scholar 

  38. •• Park J, Lertdumrongluk P, Molnar MZ, Kovesdy CP, Kalantar-Zadeh K. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr Diab Rep. 2012;12:432–9. An excellent review of what happens to type 2 diabetes after patients develop ESRD and what goal HBA1C we should aim for in this population.

    Article  PubMed  CAS  Google Scholar 

  39. Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–90.

    Article  PubMed  CAS  Google Scholar 

  40. Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, Frankel AH, Tam FW, Dornhorst A, Frost G, Turner JJ. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care. 2009;32:1137–42.

    Article  PubMed  Google Scholar 

  41. • Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, Biwole D, Kaze F, Gautier JF, Mbanya JC. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33:1409–12. A fascinating study showing that basal insulin requirements are 25 % less the day after hemodialysis in patients with ESRD and diabetes.

    Article  PubMed  CAS  Google Scholar 

  42. •• Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970–4. Reduction of initial glargine/glulisine insulin weight-based dosing (0.25 vs. 0.5 units/kg/day) in hospitalized patients with diabetes and renal insufficiency reduced the frequency of hypoglycemia by 50 % without compromising the control of hyperglycemia.

    Article  PubMed  CAS  Google Scholar 

  43. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32:1119–31.

    Article  PubMed  Google Scholar 

  44. •• Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, Seley JJ, Van den Berghe G. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16–38. The most up-to-date set of consensus guidelines for inpatients with diabetes.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Conflicts of interest: D. Baldwin has received grant support from NovoNordisk (Research Trial [LEADER]) and Sanofi-Aventis (Research Trial); J. Apel, none.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David Baldwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baldwin, D., Apel, J. Management of Hyperglycemia in Hospitalized Patients with Renal Insufficiency or Steroid-Induced Diabetes. Curr Diab Rep 13, 114–120 (2013). https://doi.org/10.1007/s11892-012-0339-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-012-0339-7

Keywords

Navigation